The biotech IPO boom continues! Goldman-backed immunotherapy newcomer Attovia (ATTO.US) raised $289 million in its IPO and will debut on Nasdaq tonight.

According to the Zhihui Finance APP, Attovia Therapeutics Inc. (ATTO.US), an early-stage biopharmaceutical company focused on diseases of the immune system and committed to addressing significant unmet clinical needs, has successfully priced its initial public offering (IPO) in the U.S. at the upper end of the price range, raising $289 million.